Resveratrol serves as a protein-substrate interaction stabilizer in human SIRT1 activation

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Hou, Xuben ^a,b   Rooklin, David ^b   Fang, Hao ^a   Zhang, Yingkai ^b,c  

^a SHANDONG UNIVERSITY   (China)

^b NEW YORK UNIVERSITY   (United States)

^c NEW YORK UNIVERSITY SHANGHAI   (China)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN BINDING; PROTEIN P53; RESVERATROL; SIRT1 PROTEIN, HUMAN; SIRTUIN 1; STILBENE DERIVATIVE;

BINDING SITE; CHEMISTRY; DRUG EFFECT; ENZYME ACTIVATION; ENZYME SPECIFICITY; HUMAN; METABOLISM; MOLECULAR DYNAMICS; PROTEIN DOMAIN; PROTEIN STABILITY;

BINDING SITES; ENZYME ACTIVATION; HUMANS; MOLECULAR DYNAMICS SIMULATION; PROTEIN BINDING; PROTEIN DOMAINS; PROTEIN STABILITY; SIRTUIN 1; STILBENES; SUBSTRATE SPECIFICITY; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84999670113     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep38186     Document Type: Article

References (63)

1. Imai, S., Guarente, L. NAD(+ ) and sirtuins in aging and disease. Trends in Cell Biol. 24, 464-471 (2014).
2. Sinclair, D. A., Guarente, L. Small-Molecule Allosteric Activators of Sirtuins. Annu. Rev. Pharmacol. 54, 363-380 (2014).
3. Guarente, L. Sirtuins and ageing-new findings. EMBO Rep. 14, 750-750 (2013).
4. Hubbard, B. P., Sinclair, D. A. Small molecule SIRT1 activators for the treatment of aging and age-related diseases. Trends Pharmacol. Sci. 35, 146-154 (2014).
5. Guarente, L. Calorie restriction and sirtuins revisited. Genes Dev. 27, 2072-2085 (2013).
6. Guarente, L., Picard, F. Calorie restriction-the SIR2 connection. Cell 120, 473-482 (2005).
7. Baur, J. A., Ungvari, Z., Minor, R. K., Le Couteur, D. G., de Cabo, R. Are sirtuins viable targets for improving healthspan and lifespan? Nat. Rev. Drug Discovery 11, 443-461 (2012).
8. Chen, D., Steele, A. D., Lindquist, S., Guarente, L. Increase in activity during calorie restriction requires Sirt1. Science 310, 1641-1641 (2005).
9. Banks, A. S. et al. SirT1 Gain of Function Increases Energy Efficiency and Prevents Diabetes in Mice. Cell Metab. 8, 333-341 (2008).
10. Bordone, L. et al. SIRT1 transgenic mice show phenotypes resembling calorie restriction. Aging Cell 6, 759-767 (2007).
11. Satoh, A. et al. Sirt1 Extends Life Span and Delays Aging in Mice through the Regulation of Nk2 Homeobox 1 in the DMH and LH. Cell Metab. 18, 416-430 (2013).
12. Herranz, D. et al. Sirt1 improves healthy ageing and protects from metabolic syndrome-associated cancer. Nat. Commun. 1, 3 (2010).
13. Satoh, A., Imai, S. I. Systemic regulation of mammalian ageing and longevity by brain sirtuins. Nat. Commun. 5, 4211 (2014).
14. Cohen, H. Y. et al. Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase. Science 305, 390-392 (2004).
15. Chen, D. et al. Tissue-specific regulation of SIRT1 by calorie restriction. Genes Dev. 22, 1753-1757 (2008).
16. Rodgers, J. T. et al. Nutrient control of glucose homeostasis through a complex of PGC-1 alpha and SIRT1. Nature 434, 113-118 (2005).
17. Schenk, S. et al. Sirt1 enhances skeletal muscle insulin sensitivity in mice during caloric restriction. J. Clin. Invest. 121, 4281-4288 (2011).
18. Kume, S. et al. Calorie restriction enhances cell adaptation to hypoxia through Sirt1-dependent mitochondrial autophagy in mouse aged kidney. J. Clin. Invest. 120, 1043-1055 (2010).
19. IBaur, J. A., Sinclair, D. A. Therapeutic potential of resveratrol: the in vivo evidence. Nat. Rev. Drug Discovery 5, 493-506 (2006).
20. Diaz-Gerevini, G. T. et al. Beneficial action of resveratrol: How and why? Nutrition 32, 174-178 (2016).
21. Price, N. L. et al. SIRT1 Is Required for AMPK Activation and the Beneficial Effects of Resveratrol on Mitochondrial Function. Cell Metab. 15, 675-690 (2012).
22. Tennen, R. I., Michishita-Kioi, E., Chua, K. F. Finding a Target for Resveratrol. Cell 148, 387-389 (2012).
23. Chung, J. H., Manganiello, V., Dyck, J. R. B. Resveratrol as a calorie restriction mimetic: therapeutic implications. Trends in Cell Biol. 22, 546-554 (2012).
24. Howitz, K. T. et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 425, 191-196 (2003).
25. IWood, J. G. et al. Sirtuin activators mimic caloric restriction and delay ageing in metazoans. Nature 430, 686-689 (2004).
26. Baur, J. A. et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 444, 337-342 (2006).
27. Kaeberlein, M. et al. Substrate-specific activation of sirtuins by resveratrol. J. Biol. Chem. 280, 17038-17045 (2005).
28. Borra, M. T., Smith, B. C., Denu, J. M. Mechanism of human SIRT1 activation by resveratrol. J. Biol. Chem. 280, 17187-17195 (2005).
29. Dai, H. et al. SIRT1 activation by small molecules: kinetic and biophysical evidence for direct interaction of enzyme and activator. J. Biol. Chem. 285, 32695-32703 (2010).
30. Pacholec, M. et al. SRT1720, SRT2183, SRT1460, and Resveratrol Are Not Direct Activators of SIRT1. J. Biol. Chem. 285, 8340-8351 (2010).
31. Cao, D. F. et al. Structural basis for allosteric, substrate-dependent stimulation of SIRT1 activity by resveratrol. Genes Dev. 29, 1316-1325 (2015).
32. Dai, H. et al. Crystallographic structure of a small molecule SIRT1 activator-enzyme complex. Nat. Commun. 6, 7645 (2015).
33. Lakshminarasimhan, M., Rauh, D., Schutkowski, M., Steegborn, C. Sirt1 activation by resveratrol is substrate sequence-selective. Aging 5, 151-154 (2013).
34. Hubbard, B. P. et al. Evidence for a Common Mechanism of SIRT1 Regulation by Allosteric Activators. Science 339, 1216-1219 (2013).
35. Rooklin, D., Wang, C., Katigbak, J., Arora, P. S., Zhang, Y. AlphaSpace: Fragment-Centric Topographical Mapping To Target Protein-Protein Interaction Interfaces. J. Chem. Inf. Model. 55, 1585-1599 (2015).
36. Milne, J. C. et al. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature 450, 712-716 (2007).
37. Cosgrove, M. S. et al. The structural basis of sirtuin substrate affinity. Biochemistry 45, 7511-7521 (2006).
38. Avalos, J. L. et al. Structure of a Sir2 enzyme bound to an acetylated p53 peptide. Mol. Cell 10, 523-535 (2002).
39. Gut, P., Verdin, E. Rejuvenating SIRT1 Activators. Cell Metab. 17, 635-637 (2013).
40. Liu, B. H. et al. Resveratrol Rescues SIRT1-Dependent Adult Stem Cell Decline and Alleviates Progeroid Features in Laminopathy-Based Progeria. Cell Metab. 16, 738-750 (2012).
41. Kim, E. J., Kho, J. H., Kang, M. R., Um, S. J. Active regulator of SIRT1 cooperates with SIRT1 and facilitates suppression of p53 activity. Mol. Cell 28, 513-513 (2007).
42. Hsu, H. C. et al. Structural basis for allosteric stimulation of Sir2 activity by Sir4 binding. Genes Dev. 27, 64-73 (2013).
43. Aeluri, M. et al. Small Molecule Modulators of Protein-Protein Interactions: Selected Case Studies. Chem. Rev. 114, 4640-4694 (2014).
44. Milroy, L. G., Grossmann, T. N., Hennig, S., Brunsveld, L., Ottmann, C. Modulators of Protein-Protein Interactions. Chem. Rev. 114, 4695-4748 (2014).
45. Giordanetto, F., Schafer, A., Ottmann, C. Stabilization of protein-protein interactions by small molecules. Drug Discovery Today 19, 1812-1821 (2014).
46. Choi, J. W., Chen, J., Schreiber, S. L., Clardy, J. Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP. Science 273, 239-242 (1996).
47. Liang, J., Choi, J., Clardy, J. Refined structure of the FKBP12-rapamycin-FRB ternary complex at 2. 2 angstrom resolution. Acta Crystallogr. 55, 736-744 (1999).
48. Yang, H. J. et al. mTOR kinase structure, mechanism and regulation. Nature 497, 217-223 (2013).
49. Aylett, C. H. S. et al. Structural Biology Architecture of human mTOR complex 1. Science 351, 48-52 (2016).
50. Dolinsky, T. J., Nielsen, J. E., McCammon, J. A., Baker, N. A. PDB2PQR: an automated pipeline for the setup of Poisson-Boltzmann electrostatics calculations. Nucleic Acids Res. 32, W665-W667 (2004).
51. Shi, Y. W., Zhou, Y. Z., Wang, S. L., Zhang, Y. K. Sirtuin Deacetylation Mechanism and Catalytic Role of the Dynamic Cofactor Binding Loop. J. Phys. Chem. Lett. 4, 491-495 (2013).
52. Case, D. A. et al. AMBER 14, University of California, San Francisco, http://ambermd. org/(2014).
53. Maier, J. A. et al. ff14SB: Improving the Accuracy of Protein Side Chain and Backbone Parameters from ff99SB. J. Chem. Theory Comput. 11, 3696-3713 (2015).
54. Peters, M. B. et al. Structural Survey of Zinc-Containing Proteins and Development of the Zinc AMBER Force Field (ZAFF). J. Chem. Theory Comput. 6, 2935-2947 (2010).
55. Papamokos, G. V. et al. Structural Role of RKS Motifs in Chromatin Interactions: A Molecular Dynamics Study of HP1 Bound to a Variably Modified Histone Tail. Biophys. J. 102, 1926-1933 (2012).
56. Ryde, U. On the Role of Glu-68 in Alcohol-Dehydrogenase. Protein Sci. 4, 1124-1132 (1995).
57. Frisch, M. J. et al. Gaussian 09. (Gaussian, Inc., Wallingford, CT, USA, 2009).
58. Cieplak, P., Cornell, W. D., Bayly, C., Kollman, P. A. Application of the Multimolecule and Multiconformational Resp Methodology to Biopolymers-Charge Derivation for DNA, Rna, and Proteins. J. Comput. Chem. 16, 1357-1377 (1995).
59. Bayly, C. I., Cieplak, P., Cornell, W. D., Kollman, P. A. A Well-Behaved Electrostatic Potential Based Method Using Charge Restraints for Deriving Atomic Charges-the Resp Model. J Phys. Chem. 97, 10269-10280 (1993).
60. Salomon-Ferrer, R., Gotz, A. W., Poole, D., Le Grand, S., Walker, R. C. Routine Microsecond Molecular Dynamics Simulations with AMBER on GPUs. 2. Explicit Solvent Particle Mesh Ewald. J. Chem. Theory Comput. 9, 3878-3888 (2013).
61. Gotz, A. W. et al. Routine Microsecond Molecular Dynamics Simulations with AMBER on GPUs. 1. Generalized Born. J. Chem. Theory Comput. 8, 1542-1555 (2012).
62. Schrödinger, L. The PyMOL Molecular Graphics System, Version 1. 7. 4 Schrödinger, LLC.
63. Pettersen, E. F. et al. UCSF Chimera-a visualization system for exploratory research and analysis. J. Comput. Chem. 25, 1605-1612 (2004).